A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

Inclusion Criteria Patients must have: * CD4+ cell count \>= 100 /mm3. * Plasma HIV RNA \>= 30,000 copies/ml. * Study participants may be recruited from all clinical categories, provided they do not meet any of the exclusion criteria. * Parent or legal guardian to sign written, informed consent for patients under the age of 18. Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms or conditions are excluded: * Patients with active or ongoing AIDS-defining opportunistic infection or disease. NOTE: * For this study, a CD4+ cell count \<= 200 cells/mm3 in the absence of any other AIDS defining indicator condition is not considered an AIDS defining event. * Malabsorption syndrome or other gastrointestinal dysfunction that might interfere with drug absorption. * Patients with life threatening infection or other serious medical conditions whose participation may compromise patient safety. Concurrent Medication: Excluded: * Treatment with cytotoxic chemotherapeutic agents within the 24 weeks of the study. * Patients receiving other investigational drugs. * Foscarnet therapy or therapy with other agents with documented activity against HIV in vitro. * Treatment with immunomodulators. * Patients on methadone. Concurrent Treatment: Excluded: * Treatment with radiation therapy within the 24 weeks of the study. NOTE: * Localized radiation therapy may be permitted following consultation with the sponsor. Patients with any of the following prior conditions are excluded: * Subjects with a history of lymphoma. * Subjects with a history of clinically apparent pancreatitis or hepatitis within the last 6 months. Prior Medication: Excluded: * Treatment with any antiretroviral therapy with NRTIs (alone or in combination) other than those defined for each treatment group. * Treatment with any non-nucleoside RT inhibitors or protease inhibitors. * Treatment with cytotoxic chemotherapeutic agents within 1 month prior to study entry. * Investigational HIV vaccine within the past 3 months. * Immunomodulating agents such as systematic corticosteroids, interleukins, thalidomide, anticytokine agents, anti-oxidants or interferons within 1 month of study entry. Prior Treatment: Excluded: * Treatment with radiation therapy within 1 month of entry. Risk Behavior: Excluded: Patients with current alcohol or illicit drug use that, in the opinion of the principal investigator, may interfere with the patient's ability to comply with the study protocol.